Tesamorelin Before and After: What the Phase 3 Trials Measured
By DoseGauge Editorial · Updated 2026-06-13 · 5 min read
For tesamorelin, "before and after" does not mean a gallery of transformation photos. It means what the controlled Phase 3 trials actually measured. In HIV-infected adults with abdominal lipodystrophy, tesamorelin 2 mg given subcutaneously once daily reduced visceral adipose tissue (VAT) over 26 weeks compared with placebo, and that effect attenuated after participants stopped the drug. In the pivotal NEJM trial (Falutz et al., 2007), VAT decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group. Those are averages from one studied population with a specific fat-redistribution condition. They are not a general weight-loss result, and they are not a prediction for any individual.
What the trials measured
The pivotal study (Falutz et al., NEJM 2007) was a randomized, double-blind, placebo-controlled Phase 3 trial in HIV-infected adults with abdominal lipodystrophy, the fat-redistribution pattern that can develop in people living with HIV. Participants received tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks.
The primary endpoint was the percentage change in visceral adipose tissue from baseline, measured by computed tomography (CT) at the level of the abdomen. That is an imaging measure of the fat stored deep in the abdominal cavity around the organs, which is the tissue this condition causes to accumulate. The trial summarized its result as a group average of that percentage change in each arm.
The visceral fat result
The paper reported that visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group over the 26-week period. Read each number as a group average from one controlled trial in one studied population.
| Group | Change in visceral adipose tissue at 26 weeks |
|---|---|
| Tesamorelin 2 mg daily | -15.2% |
| Placebo | +5.0% |
This is a measure of visceral, abdominal fat by CT imaging. It is not a measure of whole-body scale weight, and the trial did not frame it as a body-weight or general fat-loss result. The figures describe the change in deep abdominal fat in adults who had HIV-associated lipodystrophy.
Why this is not a weight-loss number
The result above is easy to misread as a weight-loss claim, and it is not one, for several reasons.
First, the population had a specific condition: HIV-associated lipodystrophy, a fat-redistribution syndrome. The trial enrolled people with that diagnosis, not a general population seeking weight loss.
Second, the endpoint was visceral fat measured by CT imaging, not scale weight. Visceral adipose tissue is one fat depot. A change in that depot is not the same as a change in total body weight, and the two do not move in lockstep.
Third, a result observed in one population under a protocol does not automatically transfer to people who do not share that condition. Using tesamorelin for general fat loss or weight loss is off-label, and it is not what these trials studied. There is no Phase 3 trial here showing a general weight-loss outcome, because that is not the question the trials asked.
What happened after stopping
The trial program and the Egrifta labeling describe the visceral-fat effect as attenuating after the drug is discontinued. In practical terms, the reduction in visceral adipose tissue was tied to continued daily dosing rather than being a one-time, durable change. When dosing stopped, the effect on visceral fat did not simply hold. This is reported as a property of how the drug works in the studied population, and it is one more reason the trial figures should not be read as a permanent before-and-after transformation.
The approved dose versus research dosing
The FDA-approved Egrifta formulations are dosed subcutaneously once daily for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy: Egrifta SV at 1.4 mg per day, and Egrifta WR at 1.28 mg per day. The pivotal Phase 3 trial used 2 mg per day. Those numbers differ because the approved products and the original trial are not the same formulation.
The calculator on this site does math on whatever you enter. It converts a milligram dose into the units to draw at your reconstitution concentration, and it recommends no dose, no drug, and no use. For related reading, see tesamorelin side effects and what tesamorelin is.
CalculatorOpen the Tesamorelin dosage calculator ->Frequently asked questions
What results did tesamorelin show in trials?
In the pivotal Phase 3 trial (Falutz et al., NEJM 2007), visceral adipose tissue decreased by 15.2% in the tesamorelin 2 mg daily group and increased by 5.0% in the placebo group over 26 weeks, in HIV-infected adults with abdominal lipodystrophy. That is a CT-imaging measure of deep abdominal fat in a specific population, reported as a group average, not a whole-body weight result and not a prediction for any individual.
Is tesamorelin used for weight loss?
Tesamorelin is FDA-approved only for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The trials measured visceral fat in that population. Using tesamorelin for general weight loss is off-label, and it is not what the trials studied. This page reports the trial data and does not recommend any use.
How long does tesamorelin take to work?
The pivotal trial measured its primary visceral-fat endpoint at 26 weeks of once-daily dosing. That is the timeframe over which the reported change in visceral adipose tissue was observed in the studied population. It describes the trial schedule, not a promise of when any individual would see a result.
Does the fat come back after stopping tesamorelin?
The trial program and the Egrifta labeling describe the visceral-fat effect as attenuating after the drug is discontinued, meaning the reduction was tied to continued daily dosing rather than being a durable one-time change. This is reported as how the drug behaved in the studied population. A clinician is the right person to discuss what any treatment might do for you.
Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.